DocDollars

Novo Nordisk Inc

NJ · United States · Reporting entity ID 100000000144

Total reported 2019–2025
$263.0M
#50 of 2,960 reporting companies — 0.3% of all reported industry payments
$187.5M in general payments across 3,138,157 records, plus $75.5M in research funding across 4,101 records.

How it breaks down

General payments $187,504,537
Research funding $75,450,326

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Novo Nordisk Inc reported $263.0M to US doctors and teaching hospitals from 2019 to 2025, ranking #50 of 2,960 reporting companies. 29% of that was research funding and 71% general payments such as consulting, speaking, food and travel. 3,138,157 general payment records and 4,101 research records were filed.

Common questions about Novo Nordisk Inc

How much has Novo Nordisk Inc paid US doctors?

Novo Nordisk Inc reported $262,954,862 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $187,504,537 in general payments, $75,450,326 in research funding.

How does Novo Nordisk Inc rank among drug and device companies?

It ranks #50 of 2,960 reporting entities by total reported value, about 0.3% of all industry payments in the dataset.

Does a payment from Novo Nordisk Inc mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.